Cargando…
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
INTRODUCTION: Minimal residual disease (MRD) is commonly assessed in bone marrow (BM) aspirate. However, sample quality can impair the MRD measurement, leading to underestimated residual cells and to false negative results. To define a reliable and reproducible method for the assessment of BM hemodi...
Autores principales: | Vigliotta, Ilaria, Armuzzi, Silvia, Barone, Martina, Solli, Vincenza, Pistis, Ignazia, Borsi, Enrica, Taurisano, Barbara, Mazzocchetti, Gaia, Martello, Marina, Poletti, Andrea, Sartor, Chiara, Rizzello, Ilaria, Pantani, Lucia, Tacchetti, Paola, Papayannidis, Cristina, Mancuso, Katia, Rocchi, Serena, Zamagni, Elena, Curti, Antonio, Arpinati, Mario, Cavo, Michele, Terragna, Carolina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582597/ https://www.ncbi.nlm.nih.gov/pubmed/36276072 http://dx.doi.org/10.3389/fonc.2022.1001048 |
Ejemplares similares
-
P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS
por: Vigliotta, Ilaria, et al.
Publicado: (2023) -
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles
por: Mazzocchetti, G., et al.
Publicado: (2022) -
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients
por: Martello, Marina, et al.
Publicado: (2022) -
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022) -
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
por: Mancuso, Katia, et al.
Publicado: (2023)